<DOC>
	<DOCNO>NCT00740779</DOCNO>
	<brief_summary>The primary objective compare efficacy silodosin 4 8 mg daily placebo treatment subject moderate severe abacterial chronic prostatitis/chronic pelvic pain syndrome 12 week treatment period . The secondary objective compare safety silodosin 4 8 mg daily placebo .</brief_summary>
	<brief_title>Use Silodosin Treat Moderate Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome .</brief_title>
	<detailed_description>A Multi-Center , Double-Blind , Placebo-Controlled Investigation Silodosin Treatment Subjects With Moderate Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Somatoform Disorders</mesh_term>
	<mesh_term>Pelvic Pain</mesh_term>
	<mesh_term>Prostatitis</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Silodosin</mesh_term>
	<criteria>Male , least 18 year age Has total NIHCPSI total score 15 Has NIHCPSI pain score 8 Has pain pelvic region least 3 month prior screen Has previously participate Watson study silodosin Has previously receive αblocked therapy chronic prostatitis/chronic pelvic pain syndrome currently receive αblocked therapy condition Has experience ≥2 urinary tract infection within previous 12 month Has medical condition opinion investigator precludes safe participation study Has medical condition could confound efficacy evaluation Is receive ketoconazole , know potent inhibitor cytochrome P450 3A4 medication opinion investigator precludes safe participation study Is receive medication opinion investigator could confound efficacy evaluation Has participate study involve administration investigational agent within past 30 day</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>prostatitis , chronic pelvic pain</keyword>
</DOC>